Original Article
Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma
Zahra Taheri-Kadkhoda MD, PhD,
Bengt Magnusson DDS, PhD,
Marie Svensson BSc,
Claes Mercke MD, PhD,
Thomas Björk-Eriksson MD, PhD,
Corresponding Author
Zahra Taheri-Kadkhoda MD, PhD
Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
Department of Oncology, Sahlgrenska University Hospital, Göteborg, SwedenSearch for more papers by this authorBengt Magnusson DDS, PhD
Department of Oral Pathology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorMarie Svensson BSc
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorClaes Mercke MD, PhD
Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorThomas Björk-Eriksson MD, PhD
Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorZahra Taheri-Kadkhoda MD, PhD,
Bengt Magnusson DDS, PhD,
Marie Svensson BSc,
Claes Mercke MD, PhD,
Thomas Björk-Eriksson MD, PhD,
Corresponding Author
Zahra Taheri-Kadkhoda MD, PhD
Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
Department of Oncology, Sahlgrenska University Hospital, Göteborg, SwedenSearch for more papers by this authorBengt Magnusson DDS, PhD
Department of Oral Pathology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorMarie Svensson BSc
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorClaes Mercke MD, PhD
Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorThomas Björk-Eriksson MD, PhD
Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
Search for more papers by this authorAbstract
Background
We aimed to identify clinical significance of latent membrane protein 1 (LMP1), Ki-67, cyclin-B1, and epidermal growth factor receptor (EGFR), in nonendemic nasopharyngeal carcinoma (NPC).
Methods
The relation between expression of the markers in 45 NPC specimens and clinicopathological and survival variables was statistically analyzed.
Results
LMP1 was present in 33% of the tumors, and its presence was associated with advanced nodal and disease stages. Overexpression was defined as labeling index ≥ median value for Ki-67, ≥ 15% for cyclin-B1, and ≥50% for EGFR, and it was displayed in 50%, 55%, and 80% of the specimens, respectively. Strong EGFR staining intensity and not overexpression of the 3 markers was the variable with statistically significant impact on treatment outcomes in terms of worse local and locoregional tumor control rates.
Conclusions
Our results suggest that the evaluation of EGFR staining intensity in patients with NPC may identify a subgroup of patients with poor prognosis. © 2009 Wiley Periodicals, Inc. Head Neck, 2009
REFERENCES
- 1 Lee N,Xia P,Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12–22.
- 2 Kieff E. Epstein-Barr virus—increasing evidence of a link to carcinoma. N Engl J Med 1995; 333: 724–726.
- 3 Li HP,Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003; 10: 490–504.
- 4 Zheng X,Hu L,Chen F,Christensson B. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 1994; 30B: 290–295.
- 5 Miller WE,Earp HS,Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69: 4390–4398.
- 6 Akimoto T,Hunter NR,Buchmiller L,Mason K,Ang KK,Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5: 2884–2890.
- 7 Ang KK,Berkey BA,Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350–7356.
- 8 Ma BB,Poon TC,To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study. Head Neck 2003; 25: 864–872.
- 9 Chua DT,Nicholls JM,Sham JS,Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 11–20.
- 10 Leong JL,Loh KS,Putti TC,Goh BC,Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004; 114: 153–157.
- 11 Fang FM,Li CF,Chien CY,Rau KM,Huang HY. Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes. Int J Pediatr Otorhinolaryngol 2007; 71: 447–455.
- 12 Hassan KA,El-Naggar AK,Soria JC,Liu D,Hong WK,Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin Cancer Res 2001; 7: 2458–2462.
- 13 Hassan KA,Ang KK,El-Naggar AK, et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 6414–6417.
- 14 Murakami H,Furihata M,Ohtsuki Y,Ogoshi S. Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch 1999; 434: 153–158.
- 15 Kushner J,Bradley G,Young B,Jordan RC. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med 1999; 28: 77–81.
- 16 Henderson S,Rowe M,Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107–1115.
- 17 Miller WE,Mosialos G,Kieff E,Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol 1997; 71: 586–594.
- 18 Horikawa T,Sheen TS,Takeshita H,Sato H,Furukawa M,Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001; 159: 27–33.
- 19 Liu B,Chen XY. [Effect of EB virus latent membrane protein 1 on mitosis control of nasopharyngeal carcinoma cell line CNE1]. Ai Zheng 2004; 23: 512–516.
- 20 Deng L,Yang J,Zhao XR, et al. Cells in G2/M phase increased in human nasopharyngeal carcinoma cell line by EBV-LMP1 through activation of NF-kappaB and AP-1. Cell Res 2003; 13: 187–194.
- 21 Horikawa T,Yoshizaki T,Sheen TS,Lee SY,Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000; 89: 715–723.
- 22 Sarac S,Akyol MU,Kanbur B, et al. Bcl-2 and LMP1 expression in nasopharyngeal carcinomas. Am J Otolaryngol 2001; 22: 377–382.
- 23 D'Addario M,Chauvin P. Ethnic differences in the expression of Epstein-Barr virus latent membrane protein-1 mutations in nasopharyngeal carcinoma. Mutat Res 2000; 457: 69–78.
- 24 Gondhowiardjo S. Epstein-Barr virus latent membrane protein 1 (EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response. Gan To Kagaku Ryoho 2000; 27 ( Suppl 2): 323–331.
- 25 Khabir A,Karray H,Rodriguez S, et al. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2005; 2: 39.
- 26 Duraiswamy J,Sherritt M,Thomson S, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003; 101: 3150–3156.
- 27 Roland NJ,Caslin AW,Bowie GL,Jones AS. Has the cellular proliferation marker Ki67 any clinical relevance in squamous cell carcinoma of the head and neck? Clin Otolaryngol Allied Sci 1994; 19: 13–18.
- 28
Masuda M,Shinokuma A,Hirakawa N,Nakashima T,Komiyama S.
Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment.
Head Neck
1998;
20:
640–644.
10.1002/(SICI)1097-0347(199810)20:7<640::AID-HED11>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 29 Myoung H,Kim MJ,Lee JH,Ok YJ,Paeng JY,Yun PY. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006; 35: 1005–1010.
- 30
Roychowdhury DF,Tseng AJr,Fu KK,Weinburg V,Weidner N.
New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression.
Cancer
1996;
77:
1419–1426.
10.1002/(SICI)1097-0142(19960415)77:8<1419::AID-CNCR1>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 31
Kallakury BV,Sheehan CE,Rhee SJ, et al.
The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Cancer
1999;
85:
1569–1576.
10.1002/(SICI)1097-0142(19990401)85:7<1569::AID-CNCR19>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 32 Soria JC,Jang SJ,Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60: 4000–4004.
- 33 Yasuda M,Takesue F,Inutsuka S,Honda M,Nozoe T,Korenaga D. Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study. J Cancer Res Clin Oncol 2002; 128: 412–416.
- 34 Shen M,Feng Y,Gao C, et al. Detection of cyclin b1 expression in g(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res 2004; 64: 1607–1610.
- 35 Santini J,Formento JL,Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13: 132–139.
- 36 Bonner JA,Harari PM,Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–578.
- 37 Sheen TS,Huang YT,Chang YL, et al. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res 1999; 90: 1285–1292.
Citing Literature
